Neuralstem, Inc. (CUR) Receives FDA Approval to Begin First ALS Stem Cell Trial
Neuralstem Inc. has patented technology which enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. The company's technology also has the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous systems diseases such as Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig's disease. The company announced today that the US Food & Drug Administration (FDA) has approved its investigational new drug application to commence a Phase 1 trial to treat ALS or…